ASH 2026 Annual Meeting
At this year’s 68th ASH Annual Meeting and Exposition, taking place 12–15 December 2026, in New Orleans, Louisiana, we are proud to be sharing new data and engaging with the scientific community to drive progress in the care of people living with blood cancers.
Our scientific areas of focus at the
68th ASH Annual Meeting in Exposition
We are pleased to share new research presented at this year's ASH Annual Meeting and Exposition.
To learn more, please visit the congress website here
Publication Number
Title / Presenting Author
Room / Date
TBC
Collaboration
Anitocabtagene Autoleucel Following Induction Therapy in Newly Diagnosed Multiple Myeloma: Early Safety, Response, and MRD Results from the Phase 2 GEM-AnitoFIRST Study
Lead author: María-Victoria Mateos
Session Date: Sat, Dec 12
Presentation Time: 9:30 - 9:45 AM
Room: MCCNO - Hall E
613
Collaboration
A prospective clinical trial of comprehensive ablative bridging irradiation (CABI) prior to axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma
Lead author: Nicholas Figura
Session Date: Sun, Dec 13
Presentation Time: 12:00 - 12:15PM
Room: MCCNO - New Orleans Theatre C
614
Collaboration
Real-world outcomes after axicabtagene ciloleucel as 2nd- vs 3rd-line therapy in large B-cell lymphoma: a propensity score-matched analysis from the French DESCAR-T registry
Lead author: TBC
Session Date: Sat, Dec 12
Presentation Time: 12:15 - 12:30PM
Room: MCCNO - New Orleans Theatre C
TBC
Collaboration
Impact of fludarabine exposure levels during lymphodepletion on the efficacy and toxicity of Axicabtagene ciloleucel in large B-cell lymphoma: a multicenter retrospective study
Lead author: TBC
TBC
TBC
Collaboration
Access to CAR T cell therapy for adults with multiple myeloma or large B-cell lymphoma: Patient, caregiver, and clinician perspectives
Lead author: Timothy O'Connor
TBC
TBC
Collaboration
High Efficacy of Obe-cel and Brexu-cel in Patients with Extramedullary B-ALL
Lead author: Karamjeet Sandhu
TBC
Publication Number
Title / Presenting Author
Room / Date
4107
Depth of lymphodepletion, measured by IL-15 serum levels, as a modifiable risk factor for neurotoxicity and non-relapse mortality: results from large-scale protein screening across 710 patients treated with anti-CD19 CAR T cell therapy
Presenting author: Davide Bedognetti
Session Date: Sun, Dec 13
Presentation Time: 6:00 - 8:00 PM
Room: MCCNO - Hall F
2728
Collaboration
Audit of the uptake of second line axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in the welsh population with assessment of the impact of deprivation on access to and response following first line chemoimmunotherapy, on behalf of the south Wales blood and marrow transplant (SWBMT) programme
Lead author: Keith Wilson
Session Date: Sat, Dec 12
Presentation Time: 5:30 - 7:30 PM
Room: MCCNO - Hall F
2632
Collaboration
Feasibility of Outpatient Axicabtagene Ciloleucel (Axi-cel) for Relapsed/Refractory Large B-Cell Lymphoma: A Single-Centre Analysis in Canada
Presenting author: Roslyn Mainland
Session Date: Sat, Dec 12
Presentation Time: 5:30 PM - 7:30 PM
Room: MCCNO - Hall F
Publication Number
Title / Presenting Author
Room / Date
TBC
Real-world (RW) outcomes of patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in non-Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) accredited centers in France from the DESCAR-T registry
Lead author: Camille Linot
N/A